根治性同步放化疗宫颈癌患者治疗前鳞状细胞癌抗原水平的预后意义及螺旋断层放疗与容积旋转调强放疗的剂量学结果与临床毒性比较
这项回顾性研究纳入93例IB-IVA期宫颈癌患者,分析同步放化疗的预后因素,并比较不同放疗技术的毒性和剂量学参数。治疗前SCC Ag > 10 ng/mL是PFS、LRRFS和DMFS的显著预后因素。直肠V30是严重急性腹泻的显著预测因素,螺旋断层放疗显著降低直肠V30并减轻急性放疗相关腹泻的严重程度。
要点
- 治疗前SCC Ag > 10 ng/mL与较差的PFS、LRRFS和DMFS显著相关。
- 直肠V30升高与≥2级急性放疗相关腹泻可能性增加相关(OR 1.15)。
- 螺旋断层放疗的直肠V30中位值及≥2级急性腹泻发生率均低于3DCRT和VMAT。
核心结论
- 治疗前SCC Ag ≤ 10 ng/mL的患者PFS、LRRFS和DMFS优于治疗前SCC Ag > 10 ng/mL的患者。
- 直肠V30是严重急性腹泻的显著预测因素。
- 螺旋断层放疗显著降低直肠V30,减轻外照射放疗期间急性放疗相关腹泻的严重程度。
研究设计与样本
- 回顾性研究纳入93例2009年4月至2017年12月接受根治性同步放化疗的IB-IVA期宫颈癌患者。
- 9例(9.7%)接受3DCRT,43例(46.2%)接受VMAT,41例(44.1%)接受螺旋断层放疗,所有患者随后接受2D计划技术的近距离放疗。
- 比较最后30例患者不同技术的临床毒性和危及器官剂量学参数。
主要发现
- 中位随访52.0个月,分析5年OS、PFS、LRRFS和DMFS。
- Cox回归模型中,治疗前SCC Ag > 10 ng/mL对PFS(HR 2.20;95%CI 1.03-4.70;P=0.041)、LRRFS(HR 3.48;95%CI 1.07-11.26;P=0.038)和DMFS(HR 2.80;95%CI 1.02-7.67;P=0.045)是显著预后因素。
- 直肠V30升高与≥2级急性放疗相关腹泻可能性增加相关(OR 1.15;95%CI 1.10-1.30;P=0.03)。
- 螺旋断层放疗、3DCRT和VMAT的直肠V30中位值分别为56.4%、97.5%和86.5%(P<0.001)。
- 螺旋断层放疗、3DCRT和VMAT的≥2级急性腹泻发生率分别为10.0%、66.7%和54.5%(P=0.029)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To analyze the prognostic factors associated with stage IB-IVA cervical cancer in patients who underwent concurrent chemoradiation therapy (CCRT) and to compare the clinical toxicities and dosimetric parameters of organs at risk between the different radiotherapy techniques. METHODS: This retrospective study enrolled 93 patients with stage IB-IVA cervical cancer who underwent definitive CCRT between April 2009 and December 2017. Nine patients (9.7%) received 3DCRT, 43 patients (46.2%) underwent VMAT, and 41 patients (44.1%) received tomotherapy, and all of them followed by brachytherapy using a 2D planning technique. The treatment outcomes and related prognostic factors were analyzed. We also compared the clinical toxicities and dosimetric parameters between the different techniques used for the last 30 patients. RESULTS: With a median follow-up of 52.0 months, the 5-year overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRRFS), and distant metastases-free survival (DMFS) were analyzed. In a Cox proportional hazards regression model, pretreatment SCC Ag > 10 ng/mL was a significant prognostic factor for PFS (hazard ratio [HR] 2.20; 95% confidence interval [CI] 1.03-4.70; P = 0.041), LRRFS (HR, 3.48; 95% CI 1.07-11.26; P = 0.038), and DMFS (HR 2.80; 95% CI 1.02-7.67; P = 0.045). Increasing the rectal volume receiving a radiation dose exceeding 30 Gy (V30 of rectum; odds ratio [OR] 1.15; 95% CI 1.10-1.30; P = 0.03) was associated with a higher possibility of ≥ Grade 2 acute radiation therapy (RT)-related diarrhea. The median rectal V30 values were 56.4%, 97.5%, and 86.5% for tomotherapy, 3-dimensional conformal radiation therapy (3DCRT), and volumetric modulated arc therapy (VMAT), respectively (P < 0.001). In addition, the chance of experiencing ≥ Grade 2 acute diarrhea were 10.0%, 66.7%, and 54.5% for tomotherapy, 3DCRT, and VMAT, respectively (P = 0.029). CONCLUSIONS: Patients with pretreatment SCC Ag ≤ 10 ng/mL have better PFS, LRRFS, and DMFS than those with pretreatment SCC Ag > 10 ng/mL. The rectal V30 is a significant predictor of severe acute diarrhea. Tomotherapy significantly decreased the rectal V30, reducing the severity of acute RT-related diarrhea during external beam RT. Trial registration This study was approved by the institutional review board at Kaohsiung Medical University Hospital. The registration number is KMUHIRB-E(I)-20190054 and retrospectively registered on 2019/3.
引用
- Cheng YK, Kuo SH, Yen HH, et al. The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric modulated arc therapy. Radiat Oncol. 2022. PMID: 35549962. doi:10.1186/s13014-022-02063-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。